Health Partners Plans

HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Antihemophilia Agents

Phone: 215-991-4300 **Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:	
HPP Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Member Primary Phone:	NPI:	*PA PROMISe ID:*
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Line of Business: ☐ Medicaid ☐ CHIP	*Specialty Pharmacy (if applicable):*	

Drug Name:	**Strength:**
Quantity:	**Refills:**
Directions:	
Diagnosis Code:	**Diagnosis:**

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this a request for continuation with the requested drug and the patient has had a positive clinical response to the drug (i.e., This medication was previously approved by a prior authorization)?

☐ Yes ☐ No

Q2. Is the requested drug being prescribed for an indication that is included in the United States Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication?

☐ Yes ☐ No

Q3. Is the prescribed dose consistent with Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?

☐ Yes ☐ No

Q4. Is the requested product prescribed by a hematologist or hemophilia treatment center practitioner?

☐ Yes ☐ No

Q5. Does the patient have a history of contraindication to the requested medication?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Antihemophilia Agents

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:

☐ Yes ☐ No

Q6. Is this request for a non-preferred antihemophilia agent?

☐ Yes ☐ No

Q7. Is this a request for a non-preferred extended half-life factor VIII replacement agent?

☐ Yes ☐ No

Q8. Does the patient have documented failure to achieve clinical goals or a history of contraindication or intolerance to the preferred extended half-life factor VIII replacement agents approved or medically accepted for the diagnosis or indication?
Must attach documentation.

☐ Yes ☐ No

Q9. Does the patient have both of the following: A) Current history [within the past 90 days] of being prescribed the requested drug and B) Documentation from the prescriber of a medical reason to continue the non-preferred extended half-life factor VIII replacement agent (e.g. a history of inhibitors and has not developed inhibitors while using the requested agent)?
Must attach documentation.

☐ Yes ☐ No

Q10. Is this a request for a non-preferred extended half-life factor IX replacement agent?

☐ Yes ☐ No

Q11. Does the patient have documented failure to achieve clinical goals or a history of contraindication or intolerance to the preferred extended half-life factor IX replacement agents approved or medically accepted for the diagnosis or indication?
Must attach documentation.

☐ Yes ☐ No

Q12. Does the patient have both of the following: A) Current history [within the past 90 days] of being prescribed the requested drug and B) Documentation from the prescriber of a medical reason to continue the non-preferred extended half-life factor IX replacement agent (e.g. a history

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

of inhibitors and has not developed inhibitors while using the requested agent)? Note: Please attach documentation.

☐ Yes ☐ No

Q13. Is this a request for a bypassing agent (e.g. FEIBA, NovoSeven RT)?

☐ Yes ☐ No

Q14. Does the patient have a diagnosis of hemophilia A with inhibitors?

☐ Yes ☐ No

Q15. Does the patient have any of the following: A) Documented failure to achieve clinical goals with Hemlibra (emicizumab), B) Documentation from the prescriber of a medical reason why Hemlibra cannot be used, C) A current history [within the past 90 days] of being prescribed the requested agent for routine prophylaxis?

☐ Yes ☐ No

Q16. Is the requested medication being used for episodic/on-demand treatment or intermittent/periodic prophylaxis?

☐ Yes ☐ No

Q17. Does the patient have a diagnosis of one of the following: a) Hemophilia B with inhibitors; B) Acquired hemophilia; C) Congenital factor VII deficiency or D) Glanzmann's thrombasthenia?

☐ Yes ☐ No

Q18. Does the patient have documented failure to achieve clinical goals or a history of contraindication or intolerance to the preferred antihemophilia agents approved or medically accepted for the diagnosis or indication?
Must attach documentation.

☐ Yes ☐ No

Q19. Does he patient have both of the following: A) Current history [within the past 90 days] of being prescribed the requested drug and B) Documentation from the prescriber of a medical

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Member Name:	Prescriber Name:

reason to continue the non-preferred antihemophilia agent (e.g. a history of inhibitors and has not developed inhibitors while using the requested agent)?
Must attach documentation.

☐ Yes ☐ No

Q20. Is this request for Hemlibra?

☐ Yes ☐ No

Q21. Does the patient have one of the following: A) diagnosis of congenital hemophilia A with inhibitors; B) diagnosis of severe congenital hemophilia A or C) diagnosis of congenital hemophilia A and a history of at least 1 spontaneous episode of bleeding into a joint or other serious bleeding event?

☐ Yes ☐ No

Q22. Additional Information:

______________________________ ______________________________

Prescriber Signature Date

v2025

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document